TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29072018
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment using the Midnight-noon Ebb-flow method combined with syndrome differentiation for 3 months
Study: 29072018
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment for language rehabilitation
Study: 12057066
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alfa-2b (HDI)
Study: 12057066
Drug: Shorter courses
Normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter courses of HDI or vaccines
Study: 12057066
Drug: Intermediate-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose interferon
Study: 2562473
Drug: Inhaled ouabain
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ouabain (doses ranged from 50 micrograms to 5000 micrograms)
Study: 30500925
Drug: E-cigarette sampling
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-cigarette sampling (weekly supply for 3 weeks)
Study: 24166893
Drug: Calcium 2
Normalized name: docusate calcium 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 2 g
Study: 24166893
Drug: Calcium 2
Normalized name: docusate calcium 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 2 g and Vitamin D3 800 IU/d
Study: 11431615
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment with APIS MELLIFICA 9 CH and BRYONIA 9 CH
Study: 11431615
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment comprising naproxen and fluid restriction
Study: 8039540
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml grapefruit juice taken simultaneously with 10 mg coumarin
Study: 8039540
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml grapefruit juice taken 30 min prior to 10 mg coumarin
Study: 8039540
Drug: coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: coadministration of grapefruit juice with 10 mg coumarin
Study: 2646997
Drug: Epinephrine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.5 mg)
Study: 2646997
Drug: Methoxamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine (5 mg)
Study: 30816640
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously Q6M
Study: 30816640
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg orally QD
Study: 18091268
Drug: Coiling treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coiling treatment
Study: 18091268
Drug: Clipping treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clipping treatment
Study: 16127299
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg phytosterols
Study: 16127299
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg phytosterols
Study: 16127299
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg phytosterols
Study: 11908511
Drug: Short-acting beta2-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta2-agonist (salbutamol)
Study: 11908511
Drug: Long-acting beta2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta2-agonist (formoterol)
Study: 10452629
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg per week
Study: 7606068
Drug: 3-L WBI
Normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-L WBI at 2 L/h
Study: 7606068
Drug: 8-L WBI
Normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-L WBI at 2 L/h
Study: 2218650
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 20.4 g of psyllium daily
Study: 21114174
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level nitrogen laser therapy along with antitubercular treatment (ATT)
Study: 21114174
Drug: Chemotherapy (ATT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ATT only)
Study: 19281914
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg pretreatment >12 hours before coronary stenting
Study: 19281914
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose, 10 mg/d maintenance dose)
Study: 19281914
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose administered at least 15 hours before elective PCI
Study: 19281914
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg pretreatment before diagnostic catheterization
Study: 19281914
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg pretreatment before elective PCI
Study: 12585987
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplements (vitamins E and C)
Study: 10636510
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 or 150 mg/day)
Study: 10636510
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg/day)
Study: 27586249
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg for 4 weeks
Study: 15801940
Drug: Ultramolecular homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultramolecular homeopathic medicines in C-30 potency administered twice weekly for 12 weeks
Study: 1379969
Drug: Orgaran (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgaran (loading dose of 1,000 anti‐Xa units intravenously followed by 750 anti‐Xa units subcutaneously 12‐hourly)
Study: 1379969
Drug: Orgaran (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgaran (750 anti‐factor Xa units subcutaneously 12‐hourly)
Study: 1379969
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5,000 units subcutaneously 12‐hourly)
Study: 26554661
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy for 1 year
Study: 23443441
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily (n=213)
Study: 21595575
Drug: Da-Cheng-Qi decoction
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Da-Cheng-Qi decoction (DCQD) administered for 7 days
Study: 16705588
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based treatment
Study: 16705588
Drug: EFV-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV-based treatment
Study: 11747870
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive preparations (three different marketed OC preparations)
Study: 11747870
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive preparations (during treatment)
Study: 8295815
Drug: Clarithromycin suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin suspension, 7.5 mg/kg twice daily
Study: 8295815
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK suspension, 13.3 mg/kg three times per day
Study: 27809637
Drug: BBT (anthocyanin-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBT (anthocyanin-rich black soybean testa extracts), 2.5 g/d
Study: 27809637
Drug: Placebo (starch),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch), 2.5 g/d
Study: 22696266
Drug: KN38-7271 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN38-7271 high-dose (1000 μg)
Study: 22696266
Drug: KN38-7271 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: KN38-7271 low-dose (500 μg)
Study: 22696266
Drug: KN38-7271 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN38-7271 (both doses)
Study: 20683847
Drug: PEG‐IFN alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 48 weeks
Study: 20683847
Drug: PEG‐IFN alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 72 weeks
Study: 16393219
Drug: Senna (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna (24 tablets of 12 mg, divided into two doses at 1 p.m. and 9 p.m.)
Study: 16393219
Drug: PEG-ES (4-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-ES (4-L standard solution)
Study: 12482664
Drug: BBG2Na vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBG2Na vaccine
Study: 9773734
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg q.i.d. (n=105)
Study: 7921758
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral low-dose cyclophosphamide (CY) after failure of a monthly pulse regimen
Study: 7921758
Drug: Monthly pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly pulse regimen of cyclophosphamide (CY)
Study: 3078575
Drug: Oral whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral whole cell anti-ETEC vaccine (approx. 3 X 10(10) vaccine cells)
Study: 25549482
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic dose adjusted based on intra-abdominal pressure (IAP)
Study: 25549482
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic dose not adjusted based on IAP
Study: 20420960
Drug: Brief course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief course in short‐wave diathermy treatment
Study: 16150205
Drug: Tripterygium glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium glycosides tablet (TGT)
Study: 16150205
Drug: Radix Tripterygium
Normalized name: Tripterygium wilfordii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix Tripterygium hypoglaucum tablet (THT)
Study: 355183
Drug: EMD 21657
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 21657 (3 x 300 mg for 6 weeks)
Study: 19642992
Drug: Joint reminiscence
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint reminiscence groups held weekly for twelve consecutive weeks, followed by monthly maintenance sessions for a further seven months
Study: 17049992
Drug: Lactitol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (oral administration) in addition to standard medical treatment for 3 weeks
Study: 17049992
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (control group) for 3 weeks
Study: 2893189
Drug: 10 fish-oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 fish-oil capsules ('MaxEPA') daily
Study: 2893189
Drug: 10 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 placebo capsules (olive oil) daily
Study: 31102045
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser preparation
Study: 25148765
Drug: YKP10811 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: YKP10811 10 mg
Study: 25148765
Drug: YKP10811 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: YKP10811 20 mg
Study: 25148765
Drug: YKP10811 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: YKP10811 30 mg
Study: 24035957
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg) with methadone (40-120 mg)
Study: 24035957
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with methadone (40-120 mg)
Study: 21707911
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice-daily for 6 weeks
Study: 21707911
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily for 6 weeks
Study: 17135812
Drug: Resource Use
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resource Use Inventory (RUI) administered at home or in clinic
Study: 17135812
Drug: Resource Use
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resource Use Inventory (RUI) administered with help of study partners
Study: 10674594
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol (E2) 50 microg/day for 14 weeks
Study: 10674594
Drug: Identical transdermal
Normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical transdermal placebo patches
Study: 1407642
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 gm single preoperative dose)
Study: 1407642
Drug: Cefazolin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (3 gm daily for one week post-surgery)
Study: 31009765
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered oxytocin (OT)
Study: 26775631
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin (100 mg dose)
Study: 25139487
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin (two applications of 800 mg)
Study: 25139487
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (250 mg)
Study: 25139487
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (1000 mg)
Study: 17993095
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol infused at a rate of 3 to 4 mg kg(‐1) h(‐1) (Group A)
Study: 16341745
Drug: Complex pharmaceutical
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex pharmaceutical care intervention by pharmacists
Study: 8925656
Drug: Hydroxyurea (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (15 mg/kg/day titrated to maximum tolerated dose up to 35 mg/kg/day)
Study: 6199481
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) IV daily for 10 days
Study: 29508470
Drug: nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nicotine replacement therapy (NRT)
Study: 27266867
Drug: Fufangdanshen (FFDS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufangdanshen (FFDS) tablets, 3 tablets three times per day for 24 weeks
Study: 27266867
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 tablets three times per day for 24 weeks
Study: 26462765
Drug: Mucinex 1200
Normalized name: Mucinex 1200 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucinex 1200 mg (2 x 600 mg extended release tablets)
Study: 11518588
Drug: Acoustic analysis
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic analysis of voice parameters (jitter, shimmer, Fo tremor, HNR) during treatment
Study: 9623511
Drug: Thalidomide treatment
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide treatment for 1 or 2 months
Study: 9623511
Drug: Thalidomide treatment
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide treatment for 1 month
Study: 9623511
Drug: Thalidomide treatment
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide treatment for 2 months
Study: 3335825
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of estrogen-progestin preparation
Study: 29757661
Drug: Levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium administered daily either as the whole dose q 24 hr or as half the dose q 12 hr, starting at 0.1 mg/10 lb (0.022 mg/kg) for approximately 6 months
Study: 17319111
Drug: Norepinephrine, Clonidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine, Clonidine, L-NMMA (nonselective alpha-adrenoceptor agonists)
Study: 17319111
Drug: Methoxamine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine (selective alpha1-adrenoceptor agonist)
Study: 7707598
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (controls)
Study: 2710801
Drug: Onion consumption
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion consumption (70 g raw onion daily for 7 days)
Study: 2710801
Drug: Ginger consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger consumption (5 g raw ginger daily for 7 days)
Study: 31600109
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP gel
Study: 27617680
Drug: Webcam Lidcombe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Webcam Lidcombe Program treatment
Study: 27617680
Drug: Standard Lidcombe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Lidcombe Program treatment
Study: 22405570
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine followed by erlotinib at disease progression (arm A)
Study: 19885979
Drug: Selection for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection for targeted treatment effect
Study: 19885979
Drug: Prognostic targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic targeting for targeted treatment effect
Study: 17189085
Drug: Experimental formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formula containing 2 x 10(7) colony-forming units of Bifidobacterium longum BL999 and 4 g/L of prebiotic mixture (90% galacto-oligosaccharides and 10% fructo-oligosaccharides)
Study: 9892571
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intramuscular piroxicam
Study: 9892571
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg intramuscular diclofenac sodium
Study: 2126198
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined oestrogen/progestogen therapy (2 mg of 17 beta‐oestradiol combined with 1 mg of norethisterone acetate orally each day continuously for 5 years)
Study: 2126198
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined oestrogen/progestogen therapy
Study: 389150
Drug: Guanidine hydrochloride
Normalized name: Guanidine Hydrochloride
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guanidine hydrochloride (20 to 35 mg/kg per day perorally)
Study: 30412909
Drug: Indigenous Counselling
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention including educational resource packages, live interactive webinars, treatment manuals, patient resources, carbon monoxide (CO) meters, and oral Nicotine Replacement Therapy (NRT).
Study: 24994768
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance exercise (PRE) program, 12 weeks, twice a week, using machines with free weights at 50% and 70% of one-repetition maximum (1RM).
Study: 24994768
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) remained on a waiting list for physical therapy.
Study: 19118954
Drug: 10mg oxycodone
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg oxycodone (OXY)/487 mg acetaminophen (ACET)
Study: 19118954
Drug: 20mg oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg oxycodone (OXY)/975 mg acetaminophen (ACET)
Study: 19118954
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hydrocodone (HYD)/487 mg acetaminophen (ACET)
Study: 19118954
Drug: 30mg hydrocodone
Normalized name: hydrocodone bitartrate 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg hydrocodone (HYD)/975 mg acetaminophen (ACET)
Study: 19118954
Drug: 975 mg
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975 mg acetaminophen (ACET)
Study: 11374113
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage monophasic oral contraceptives (OC) - days 5-8